Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer | Zendy

Shanu Modi | Zendy; Cristina Saura | Zendy; Toshinari Yamashita | Zendy; Yeon Hee Park | Zendy; SungBae Kim | Zendy; Kenji Tamura | Zendy; Fabrice André | Zendy; Hiroji Iwata | Zendy; Yoshinori Ito | Zendy; Junji Tsurutani | Zendy; Joohyuk Sohn | Zendy; Neelima Denduluri | Zendy; Christophe Perrin | Zendy; Kenjiro Aogi | Zendy; Eriko Tokunaga | Zendy; SeockAh Im | Zendy; Keun Seok Lee | Zendy; Sara A. Hurvitz | Zendy; Javier Cortés | Zendy; Caleb Lee | Zendy; Shuquan Chen | Zendy; Lin Zhang | Zendy; Javad Shahidi | Zendy; Antoine Yver | Zendy; Ian E. Krop | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Author(s) -

Shanu Modi,

Cristina Saura,

Toshinari Yamashita,

Yeon Hee Park,

SungBae Kim,

Kenji Tamura,

Fabrice André,

Hiroji Iwata,

Yoshinori Ito,

Junji Tsurutani,

Joohyuk Sohn,

Neelima Denduluri,

Christophe Perrin,

Kenjiro Aogi,

Eriko Tokunaga,

SeockAh Im,

Keun Seok Lee,

Sara A. Hurvitz,

Javier Cortés,

Caleb Lee,

Shuquan Chen,

Lin Zhang,

Javad Shahidi,

Antoine Yver,

Ian E. Krop

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1914510

Subject(s) - trastuzumab , medicine , trastuzumab emtansine , breast cancer , metastatic breast cancer , oncology , cancer , clinical endpoint , clinical trial

Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research